{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:41:09Z","timestamp":1786635669142,"version":"build-2736575974"},"reference-count":93,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijp.ijp_310_20","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T06:12:15Z","timestamp":1591078335000},"page":"117","source":"Crossref","is-referenced-by-count":46,"title":["COVID-19 pandemic: A review based on current evidence"],"prefix":"10.4103","volume":"52","author":[{"given":"Bikash","family":"Medhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VidyaM","family":"Mahalmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Mahendru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Semwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhmeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phulen","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.285727-1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses","author":"Shereen","year":"2020","journal-title":"J Adv Res"},{"key":"key-10.4103\/0253-7613.285727-2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","article-title":"Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003","author":"Zhong","year":"2003","journal-title":"Lancet"},{"key":"key-10.4103\/0253-7613.285727-3","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2013.92","article-title":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4","author":"Wang","year":"2013","journal-title":"Cell Res"},{"key":"key-10.4103\/0253-7613.285727-4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","article-title":"The molecular biology of coronaviruses","author":"Masters","year":"2006","journal-title":"Adv Virus Res"},{"key":"key-10.4103\/0253-7613.285727-5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"key-10.4103\/0253-7613.285727-6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"#cr-split#-key-10.4103\/0253-7613.285727-7.1","unstructured":"WHO. Coronavirus Disease 2019 (COVID-19) Situation Report - 99"},{"key":"#cr-split#-key-10.4103\/0253-7613.285727-7.2","unstructured":"2020. Available from: https:\/\/www.who.int\/docs\/default-source\/coro naviruse\/situation-reports\/20200428-sitr ep-99-covid-19.pdf?sfvrsn=119fc381_2. [Last accessed on 2020 Apr 29]."},{"key":"key-10.4103\/0253-7613.285727-8","unstructured":"Ministry of Health and Family Welfare Government of India. COVID-19 INDIA as on: 29 April 2020, 08:00 GMT+5:30. Available from: https:\/\/www.mohfw.gov.in\/. [Last accessed on 2020 Apr 29]."},{"key":"key-10.4103\/0253-7613.285727-9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","author":"Chen","year":"2020","journal-title":"J Med Virol"},{"key":"key-10.4103\/0253-7613.285727-10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"key-10.4103\/0253-7613.285727-11","first-page":"1564","article-title":"Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1","author":"van","year":"2020","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.285727-12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S2468-1253(20)30048-0","article-title":"Enteric involvement of coronaviruses: Is faecal\u2013oral transmission of SARS-CoV-2 possible?","author":"Yeo","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key-10.4103\/0253-7613.285727-13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41591-020-0817-4","article-title":"Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding","author":"Xu","year":"2020","journal-title":"Nat Med"},{"key":"key-10.4103\/0253-7613.285727-14","doi-asserted-by":"crossref","unstructured":"Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 2020;158:1831-3.e3.","DOI":"10.1053\/j.gastro.2020.02.055"},{"key":"key-10.4103\/0253-7613.285727-15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41575-019-0241-8","article-title":"COVID-19: Faecal\u2013oral transmission?","author":"Hindson","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key-10.4103\/0253-7613.285727-16","doi-asserted-by":"crossref","unstructured":"Chen Y, Shan K, Qian W. Asians and Other Races Express Similar Levels of and share the Same Genetic Polymorphisms of the SARS-CoV-2 Cell-Entry Receptor Ying. Preprints 2020020258; 2020.","DOI":"10.20944\/preprints202002.0258.v1"},{"key":"key-10.4103\/0253-7613.285727-17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.phrs.2017.06.005","article-title":"The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases","author":"Li","year":"2017","journal-title":"Pharmacol Res"},{"key":"key-10.4103\/0253-7613.285727-18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"key-10.4103\/0253-7613.285727-19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"key-10.4103\/0253-7613.285727-20","unstructured":"Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020;92:568\u201376. [doi: 10.1002\/jmv. 25748]."},{"key":"key-10.4103\/0253-7613.285727-21","unstructured":"Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli D. Features, Evaluation and Treatment Coronavirus (COVID 19). In: StatPearls. StatPearls Publishing; 2020. Available from: https:\/\/ www.ncbi.nlm.nih.gov\/books\/NBK554776\/. [Last accessed on 2020 Apr 20]."},{"key":"key-10.4103\/0253-7613.285727-22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/jmv.25702","article-title":"Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring","author":"Xiao","year":"2020","journal-title":"J Med Virol"},{"key":"key-10.4103\/0253-7613.285727-23","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1128\/JCM.42.5.2306-2309.2004","article-title":"Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia","author":"Woo","year":"2004","journal-title":"J Clin Microbiol"},{"key":"key-10.4103\/0253-7613.285727-24","doi-asserted-by":"crossref","unstructured":"Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020;10.1002\/jmv.25727. [doi:10.1002\/jmv.25727].","DOI":"10.1002\/jmv.25727"},{"key":"key-10.4103\/0253-7613.285727-25","doi-asserted-by":"crossref","unstructured":"Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 2020. pii: ciaa310.","DOI":"10.1093\/cid\/ciaa310"},{"key":"key-10.4103\/0253-7613.285727-26","first-page":"1","article-title":"Therapeutic options for the treatment of 2019 \u2013 Novel coronavirus-\u00af: An evidence - based approach","author":"Sarma","year":"2020","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/0253-7613.285727-27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving drugs a second chance: Overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics","author":"Hernandez","year":"2017","journal-title":"Front Oncol"},{"key":"key-10.4103\/0253-7613.285727-28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/0253-7613.285727-29","unstructured":"US. FOOD & DRUG ADMINISTRATION. Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. Available from: https:\/\/www.fda.gov\/patients\/learn-ab out-drug-and-device-approvals\/fast-track-breakthrough-therapy-accele rated-approval-priority-review. [Last accessed on 2020 Mar 25]."},{"key":"key-10.4103\/0253-7613.285727-30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2125.2005.02435.x","article-title":"Biomarkers and surrogate endpoints","author":"Aronson","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.4103\/0253-7613.285727-31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jlb\/lsw046","article-title":"EBOLA and FDA: Reviewing the response to the 2014 outbreak, to find lessons for the future","author":"Largent","year":"2016","journal-title":"J Law Biosci"},{"key":"key-10.4103\/0253-7613.285727-32","doi-asserted-by":"crossref","first-page":"e001086","DOI":"10.1136\/bmjgh-2018-001086","article-title":"Towards global health security: Response to the May 2018 Nipah virus outbreak linked to Pteropus bats in Kerala, India","author":"Sadanadan","year":"2018","journal-title":"BMJ Glob Health"},{"key":"key-10.4103\/0253-7613.285727-33","unstructured":"Indian Council of Medical Research. Media Report (ICMR IN NEWS); 1-7 June, 2019. Available from: https:\/\/www.icmr.nic.in\/sites\/defau lt\/files\/ICMR_NEWS_JUNE.pdf. [Last accessed on 2020 Apr 08]."},{"key":"key-10.4103\/0253-7613.285727-34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"key-10.4103\/0253-7613.285727-35","doi-asserted-by":"crossref","unstructured":"Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al.In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. pii: ciaa237.","DOI":"10.1093\/cid\/ciaa237"},{"key":"key-10.4103\/0253-7613.285727-36","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;105949. [doi:10.1016\/j.ijantimicag.2020.105949].","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"key-10.4103\/0253-7613.285727-37","unstructured":"FDA. Hydroxychloroquine Sulfate Tablets, USP. Available from: https:\/\/www.accessdata.fda.gov\/drugsat fda_docs\/label\/2017\/009768s037s 045s047lbl.pdf. [Last accessed on 2020 Mar 25]."},{"key":"key-10.4103\/0253-7613.285727-38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/0897190013516503","article-title":"Azithromycin and the risk of cardiovascular complications","author":"Maisch","year":"2014","journal-title":"J Pharm Pract"},{"key":"key-10.4103\/0253-7613.285727-39","unstructured":"Indian Council of Medical Research. Advisory on the use of Hydroxy-Chloroquine as Prophylaxis for SARS-COV2 Infection. Indian Council of Medical Research; 2020. Available from: https:\/\/www.mohfw.gov.in\/pdf\/Advisory ontheuseofHydroxychloroquinasprophylaxi sforSARSCoV2infection.pdf. [Last accessed on 2020 Apr 05]."},{"key":"key-10.4103\/0253-7613.285727-40","unstructured":"Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and clinical cure in Covid-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol 2020;10.1002\/jmv.25898. [doi: 10.1002\/jmv. 25898]."},{"key":"key-10.4103\/0253-7613.285727-41","doi-asserted-by":"crossref","unstructured":"Chen C, Huang J, Yin P, Zhang Y, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for COVID 19: A randomized clinical trial. MedRxiv. 2020. Available from: https:\/\/www.medrxiv.org\/con tent\/10.1101\/2020.03.17.20037432v3. [ Last accessed on 2020 Mar 25].","DOI":"10.1101\/2020.03.17.20037432"},{"key":"key-10.4103\/0253-7613.285727-42","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","author":"Morse","year":"2020","journal-title":"Chembiochem"},{"key":"key-10.4103\/0253-7613.285727-43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"key-10.4103\/0253-7613.285727-44","unstructured":"Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of remdesivir for patients with severe Covid-19. N Engl J Med 2020. pii: NEJMoa2007016."},{"key":"key-10.4103\/0253-7613.285727-45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","author":"Chen","year":"2004","journal-title":"J Clin Virol"},{"key":"key-10.4103\/0253-7613.285727-46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1177\/1060028015597449","article-title":"Oral ribavirin for the treatment of noninfluenza respiratory viral infections: A systematic review","author":"Gross","year":"2015","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/0253-7613.285727-47","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/cid\/ciz544","article-title":"Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: A multicenter observational study","author":"Arabi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0253-7613.285727-48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: Initial virological and clinical findings","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"key-10.4103\/0253-7613.285727-49","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020. pii: NEJMoa2001282."},{"key":"key-10.4103\/0253-7613.285727-50","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"key-10.4103\/0253-7613.285727-51","first-page":"e01753","article-title":"Complement Activation contributes to severe acute respiratory syndrome coronavirus pathogenesis","author":"Gralinski","year":"2018","journal-title":"mBio"},{"key":"key-10.4103\/0253-7613.285727-52","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology","author":"Channappanavar","year":"2017","journal-title":"Semin Immunopathol"},{"key":"key-10.4103\/0253-7613.285727-53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"key-10.4103\/0253-7613.285727-54","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S2213-2600(13)70259-5","article-title":"The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: An open-label study","author":"Bellingan","year":"2014","journal-title":"Lancet Respir Med"},{"key":"key-10.4103\/0253-7613.285727-55","unstructured":"Hope Biosciences. FDA Approval to CommenceFirst Stem Cell Clinical Trial for Protection Against COVID-19. Available from: https:\/\/www.hope.bio\/post\/fda-approval-to-commence- first-stem-cell-clini cal-trial-for-protection-against-covid-19. [Last accessed on 2020 Apr 23]."},{"key":"key-10.4103\/0253-7613.285727-56","unstructured":"Athersys Inc. FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem\u00ae Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome. Available from: https:\/\/www.athersys.com\/investors\/pre ss-releases\/press-release-details\/2020\/F DA-Authorizes-Athersys-to-Initiate-a-P ivotal-Clinical-Trial-Evaluating-MultiStem-C ell-Therapy-in-Patients-With-COVID-19-Indu ced-Acute-Respiratory-Distress-Syn drome\/default.aspx. [Last accessed on 2020 Apr 23]."},{"key":"key-10.4103\/0253-7613.285727-57","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: Systematic review of treatment effects","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"key":"key-10.4103\/0253-7613.285727-58","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with middle east respiratory syndrome","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.4103\/0253-7613.285727-59","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"key-10.4103\/0253-7613.285727-60","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMsr1408795","article-title":"Middle east respiratory syndrome","author":"Arabi","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.285727-61","unstructured":"WHO. Clinical Management of Severe Acute Respiratory Infection when COVID-19 is Suspected. Available from: https:\/\/www.who.int\/publications-detail\/c linical-management-of -severe-acute-resp ratory-infection-when-novel-coron avirus-(ncov)-infection-is-suspected. [Last accessed on 2020 Apr 05]."},{"key":"key-10.4103\/0253-7613.285727-62","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome\/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)","author":"Zhou","year":"2016","journal-title":"J Biol Chem"},{"key":"key-10.4103\/0253-7613.285727-63","doi-asserted-by":"crossref","unstructured":"Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin Potently Blocks the Cell Entry of 2019-nCoV. BioRxiv; 2020.","DOI":"10.1101\/2020.02.05.935387"},{"key":"key-10.4103\/0253-7613.285727-64","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"key-10.4103\/0253-7613.285727-65","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","author":"Wagstaff","year":"2012","journal-title":"Biochem J"},{"key":"key-10.4103\/0253-7613.285727-66","first-page":"56","article-title":"Drug targets for corona virus: A systematic review","author":"Prajapat","year":"2020","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/0253-7613.285727-67","doi-asserted-by":"crossref","unstructured":"Sarma P, Sekhar N, Prajapat M, Avti P, Kaur H, Kumar S, et al. In silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). J Biomol Struct Dyn 2020;2020;1-9. [doi: 10.1080\/07391102.2020.1753580].","DOI":"10.1080\/07391102.2020.1753580"},{"key":"key-10.4103\/0253-7613.285727-68","doi-asserted-by":"crossref","unstructured":"Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS 2020:202004168. [doi: https:\/\/doi.org\/10.1073\/pnas. 2004168117].","DOI":"10.1073\/pnas"},{"key":"key-10.4103\/0253-7613.285727-69","unstructured":"WHO. Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease. Available from: https:\/\/www.who.int\/csr\/resources\/pu blications\/ebola\/convalesc ent-treatment\/en\/. [Last accessed on 2020 Apr 06]."},{"key":"key-10.4103\/0253-7613.285727-70","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0253-7613.285727-71","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key-10.4103\/0253-7613.285727-72","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0253-7613.285727-73","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.7150\/ijbs.45538","article-title":"Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"key-10.4103\/0253-7613.285727-74","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ptr.1485","article-title":"Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS","author":"Chen","year":"2004","journal-title":"Phytother Res"},{"key":"key-10.4103\/0253-7613.285727-75","first-page":"266","article-title":"TCM treatment of infectious atypical pneumonia \u2013 A report of 16 cases","author":"Tong","year":"2004","journal-title":"J Tradit Chin Med"},{"key":"key-10.4103\/0253-7613.285727-76","first-page":"CD004882","article-title":"Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS)","author":"Liu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0253-7613.285727-77","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.3748\/wjg.v10.i23.3500","article-title":"Effect of integrated traditional Chinese and Western medicine on SARS: A review of clinical evidence","author":"Zhang","year":"2004","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/0253-7613.285727-78","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1089\/acm.2004.10.1041","article-title":"Chinese herbal medicine for severe acute respiratory syndrome: A systematic review and meta-analysis","author":"Liu","year":"2004","journal-title":"J Altern Complement Med"},{"key":"key-10.4103\/0253-7613.285727-79","unstructured":"AYUSH. Advisory for Corona Virus. Available from: https:\/\/pib.gov.in\/PressReleasePa ge.aspx?PRID=1600895. [Last accessed on 2020 Mar 28]."},{"key":"key-10.4103\/0253-7613.285727-80","unstructured":"WHO. DRAFT Landscape of COVID-19 Candidate Vaccines \u2013 20 April 2020. Available from: https:\/\/www.who.int\/blueprint\/priority-dis eases\/key-action\/novel-coronavirus-land scape-ncov.pdf. [Last accessed on 2020 Apr 29]."},{"key":"key-10.4103\/0253-7613.285727-81","unstructured":"Chinese Clinical Trial Registry. Randomized, Double-Blinded, Placebo-Controlled Phase II Clinical Trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector). Available from: http:\/\/www.chictr.org.cn\/showpr ojen.aspx?proj=52006. [Last accessed on 2020 Apr 29]."},{"key":"key-10.4103\/0253-7613.285727-82","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/d41586-020-00751-9","article-title":"Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees","author":"Jiang","year":"2020","journal-title":"Nature"},{"key":"key-10.4103\/0253-7613.285727-83","first-page":"1689","article-title":"Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: An epidemiological study","author":"Miller","year":"2013","journal-title":"J Chem Inf Model"},{"key":"key-10.4103\/0253-7613.285727-84","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.cmi.2019.04.020","article-title":"Non-specific effects of BCG vaccine on viral infections","author":"Moorlag","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"key-10.4103\/0253-7613.285727-85","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"key-10.4103\/0253-7613.285727-86","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","author":"Wang","year":"2020","journal-title":"Biosci Trends"},{"key":"key-10.4103\/0253-7613.285727-87","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"key-10.4103\/0253-7613.285727-88","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","author":"Jun","year":"2020","journal-title":"J Zhejiang Univ (Med Sci)"},{"key":"key-10.4103\/0253-7613.285727-89","unstructured":"WHO. Laboratory Testing Strategy Recommendations for COVID-19. Interim Guidance 21 March 2020. Available from: https:\/\/apps.who.int\/iris\/bitstream\/ha ndle\/10665\/331509\/WHO-COVID-19-la b_testing-2020.1-eng.pdf. [Last accessed on 2020 Apr 09]."},{"key":"key-10.4103\/0253-7613.285727-90","unstructured":"Ministry of Health Singapore. Being Prepared for a Pandemic. Available from: https:\/\/www.moh.gov.sg\/diseases-upda tes\/being-prepared-for-a-pandemic. [Last accessed on 2020 Apr 09]."},{"key":"key-10.4103\/0253-7613.285727-91","unstructured":"Indian Council of Medical Research. National Ethical Guidelines for Biomedical and Health Research Involving Human Participants. New Delhi: ICMR; 2017. Available from: https\/\/www.icmr.nic.in\/sites\/defa ult\/files\/guidelines\/ICMR_ Ethical_Guidelines_2017.pdf. [Last accessed on 2020 Apr 09]."},{"key":"key-10.4103\/0253-7613.285727-92","unstructured":"New Drugs and Clinical Trials Rules 2019 G.S.R. 227(E). CDSCO 2019;1940:147-264. Available from: https:\/\/cdsco.gov.in\/opencms\/opencms\/sys tem\/modules\/CDSCO.WEB\/elements\/down load_file_division.jsp?num_id=NDI2MQ==. [Last accessed on 2020 Apr 09]."}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:48:45Z","timestamp":1786632525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_310_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["285727"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_310_20","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}